FOLFOX 2 regimen in heavily pretreated patients with advanced colorectal cancer

Tumori

Volumn 88, Issue 4, 2002, Pages 270-272

  Luppi, Gabriele ^a   Zanelli, Francesca ^a   Di Stasi, Antonio ^a   Bertolini, Federica ^a   Pifferi, Micol ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Advanced colorectal cancer; Chemotherapy; Oxaliplatin

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYTOTOXIC AGENT; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOMUSTINE; METHOTREXATE; MITOMYCIN C; OXALIPLATIN; SPARFOSIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; MALE; MUCOSA INFLAMMATION; NAUSEA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0036657783     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160208800404     Document Type: Article

References (13)

1. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol, 10: 896-903, 1992.
2. Advanced Colorectal Cancer Meta-Analysis Project: Meta-analysis of randomised trials testing the biochemical modulation of 5-fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol, 12: 960-969, 1994.
3. Bowen Benson III A: Therapy for advanced colorectal cancer. Semin Oncol, 25: 2-11, 1998.
4. Meta-Analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol, 16: 301-308, 1998.
5. Rotenberg ML, Blanke CD: Topoisomerase I inhibitors in the treatment of colorectal cancer. Semin Oncol, 26: 632-639, 1999.
6. Rougier P, Bugat R: CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin Oncol, 23: 34-41, 1996.
7. Gerard B, Bleiberg H, Michel J: Oxaliplatin combined to 5-FU and folinic acid as second or third line treatment in patients with advanced colorectal cancer. PROC ASCO, 17: 273a, 1997.
8. Giacchetti S, Zidani R, Perpoint B, Pinel MC, Faggiuolo R, Focan C, Letourneau Y, Chollet P, Llory JF, Coudert B, Bertheault-Cvitkovic F, Adam R, Le Bail N, Misset JL, Bayssas M, Lévi F for the International Organization for Cancer Chemotherapy, FMSIT Hòpital P Brousse, Villejuif. and Debiopharm SA: Phase III trial of 5-fluorouracil, folinic acid, with or without oxaliplatin in previously untreated patients with colorectal cancer. Am Soc Clin Oncol, 16: 805, 1997.
9. Machover D, Diaz-Rubio E, De Gramont A: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines, Ann Oncol, 7: 95-98, 1996.
10. Cvitkovic E, Bekradda M: Oxaliplatin: a new therapeutic option in colorectal cancer, Semin Oncol, 26: 647-662, 1999.
11. De Gramont A, Figer A, Seymour M: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol, 18: 2938-2947, 2000.
12. De Gramont A, Vignoud J, Tournigand C, Louvet C, André T, Varette C, Raymond E, Moreau S, Le Bail N, Krulik M: Oxaliplatin with high-dose leucovorin and fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer, 33: 214-219, 1997.
13. Mosconi S, Cascinu S, Zaniboni A, Catalano V, Giordani P, Beretta GD, Martignoni G, Pancera G, Baldelli AM, Poletti P, Curti C, Labianca R: The value of oxaliplatin in combination with continuous infusion ± bolus 5-fluorouracil and levofolinic acid in metastatic colorectal cancer progressing after 5FU-based chemotherapy: a GISCAD (Italian Group for the Study of Digestive Tract) cancer phase II trial. Tumori, 86: 465-469, 2000.